Rivus Pharmaceuticals
Charlottesville, United States · Biotechnology, Health Care · 27 employees
Rivus Pharmaceuticals, Inc., is dedicated to transforming the treatment of cardio-metabolic disease by advancing a new class of oral, once daily, small molecule therapeutics called Controlled Metabolic Accelerators (CMAs). Rivus’ CMAs are designed to improve cellular metabolism and treat the underlying cause of highly prevalent metabolic and cardiovascular diseases including type 2 diabetes, sever
Funding history
- Funding Round — $57.0M — Jan 2025
- Funding Round — $66.0M — Sep 2024
- Series series b — $132.0M — Sep 2022
- Funding Round — $34.5M — Oct 2021
Recent signals
- Feb 26, 2026: Rivus Pharmaceuticals Appoints Jorge Bartolome as Chief Executive Officer
- Apr 10, 2025: Rivus Pharmaceuticals Appoints Meg Fitzgerald as Chief Legal Officer
- Jan 16, 2025: Raised $57.0M
- Sep 17, 2024: Raised $66.0M
- Jun 29, 2023: Rivus Pharmaceuticals Announces Leadership Transition, Appointment of Jayson Dallas, M.D., as CEO
- Sep 22, 2022: Raised $132.0M in Series series b
- Oct 04, 2021: Raised $34.5M
See plans & pricing → Track Rivus Pharmaceuticals’s funding, hiring, and signals — with verified contacts — on Fundz.